Clontech Laboratories, Inc. Licenses CRISPR/Cas9 Technology From The Broad Institute

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that they have entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. "Clontech is pleased to be able to provide innovative tools for CRISPR/Cas9 gene editing under our Guide-it brand," commented Carol Lou, General Manager of Clontech Laboratories, Inc. "We believe that CRISPR/Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use.

http://ift.tt/ZTBKUh